Literature DB >> 28616905

[Clinicopathological Features, Diagnoses and Treatments of 6 458 Lung Cancer Patients].

Lei Li1, Dan Liu1, Li Zhang2, Ping Zhou1, Juan Song1, Yue Cheng1, He Yu1, Shuang Zhao1, Wei-Min Li1.   

Abstract

OBJECTIVES: Lung cancer is the leading cause of cancer-related death on a global scale. This study aimed to review the clinicopathological featuresof primary lung cancer and the practice in diagnoses and treatments.
METHODS: Medical record of patients diagnosed with primary lung cancer in West China Hospital of Sichuan University from 2008 to 2014 were retrospectively reviewed. Clinical characteristics of the patients, including pathological type, age, gender, and TNM stage were analyzed.
RESULTS: A total of 6 458 patients were diagnosed with primary lung cancer, with male patients comprising the majority (male: 66.5%, n=4 291 vs. female: 33.5%, n=2 167). The patients had an average age of 59.22 yr., mostly (61.1%) between 50 and 70 yr. and 5.1% (n=335) under 40 yr. More than half (53.3%) of the patients were at stage IV at diagnosis, compared with 10.5% at stage I. The most common histological type was adenocarcinoma (ADC, n=3 523, 54.44%), followed by squamous cell carcinoma (SCC, n=1 637, 25.35%) and small cell lung cancer (SCLC, n=916, 14.18%). The majority of patients were confirmed with fibrobronchoscopy and surgery, and treated with surgery and chemotherapy.
CONCLUSIONS: Patients diagnosed with primary lung cancer in West China Hospital of Sichuan University are primarily elderly men. Adenocarcinoma is the main type. Fibrobronchoscopyis the main method for diagnosis, and chemotherapy and surgery are the main treatments for lung cancer.

Entities:  

Keywords:  Clinical epidemiologyzzm321990; Diagnosis and treatmentszzm321990; Histologic typezzm321990; Lung neoplasmzzm321990

Mesh:

Year:  2017        PMID: 28616905

Source DB:  PubMed          Journal:  Sichuan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-173X


  3 in total

Review 1.  Implementation planning for lung cancer screening in China.

Authors:  Yue I Cheng; Michael P A Davies; Dan Liu; Weimin Li; John K Field
Journal:  Precis Clin Med       Date:  2019-03-14

2.  Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone.

Authors:  Yujia Wang; Guoyu Wu; Ru Li; Yingzhe Luo; Xingmei Huang; Lifang He; Huihui Zhong; Shaoquan Xiong
Journal:  Front Public Health       Date:  2021-06-18

Review 3.  [Progress of Lung Cancer Screening with Low Dose Helical Computed Tomography].

Authors:  Mengna Wei; Youlin Qiao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-08-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.